Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemoradiation for Esophageal/EGJ Cancer
NCT05245760Phase 2Withdrawn
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in esophageal cancer and esophagogastric junction cancer. Primary endpoint: Pathological Complete Response Rate at 12 months. Planned start Apr 2022; status: withdrawn.
02
Drugs
tislelizumab
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NCT05245760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245760.